Ardelyx, Inc. (ARDX)
Ardelyx, Inc. (ARDX) is a biotechnology company focused on developing and commercializing novel treatments for cardio-renal and gastrointestinal diseases. Founded to address unmet medical needs, Ardelyx's portfolio includes therapies targeting conditions such as chronic kidney disease, constipation, and other gastrointestinal disorders.
Company News
Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Ardelyx (NASDAQ:ARDX) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 2 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.4, a high estimate of $15.00, and a low estimate of $14.00. Marking an increase of 8.03%, the current average surpasses the previous average price target of $13.33. Analyzing Analyst Ratings: A Detailed Breakdown The standing of Ardelyx among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Laura Chico Wedbush Maintains Outperform $15.00 - Yigal Nochomovitz Citigroup Raises Buy $14.00 $13.00 Laura Chico Wedbush Raises Outperform $15.00 $14.00 Laura Chico Wedbush Raises Outperform $14.00 $13.00 Roanna Ruiz Leerink Partners Announces Outperform $14.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ardelyx. This information provides a snapshot of ...Full story available on Benzinga.com
Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to buy? Here are some of the most active under $5 to watch. The post Penny Stocks To Buy Now? 5 Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.